Skip to main content
. 2022 Jan 12;42(2):163–175. doi: 10.1007/s40261-021-01114-6

Fig. 2.

Fig. 2

Cost-effectiveness plane of the probabilistic sensitivity analysis for base-case model in the cost-effectiveness analysis of therapeutic drug monitoring of tamoxifen adjuvant therapy versus standard of care (without TDM intervention). Straight line indicates the Dutch conservative willingness-to-pay threshold of €20,000. All model simulations below this threshold are considered cost-effective from a healthcare perspective